Table 2.
Distribution of Clinical Characteristics Between Paxlovid Treatment Groups
| Negative | Use Beyond Five Days of Symptom Onset | Single Use Within Five Days of Symptom Onset | Combining Use with Dexamethasone Within Five Days of Symptom Onset | p | |
|---|---|---|---|---|---|
| Age*, median (IQR) | 58.0 (33.0) | 68.0 (16.0) | 66.0 (21.0) | 58.0 (39.5) | <0.001 |
| Cycle threshold value*, median (IQR) | 26.2 (10.5) | 35.3 (7.5) | 25.0 (13.6) | 28.9 (19.7) | <0.001 |
| Gender†, n (%) | <0.001 | ||||
| Male | 277 (70.5) | 87 (22.1) | 18 (4.6) | 11 (2.8) | |
| Female | 339 (86.3) | 37 (9.4) | 15 (3.8) | 2 (0.5) | |
| Clinical classification of COVID-19*, n (%) | <0.001 | ||||
| Asymptomatic infection | 141 (97.9) | 2 (1.4) | 1 (0.7) | 0 (0) | |
| Mild and moderate illness | 435 (79.7) | 81 (14.8) | 25 (4.6) | 5 (0.9) | |
| Severe and critical illness | 40 (42.1) | 41 (43.2) | 7 (7.4) | 7 (7.4) | |
| Comorbidities†, n (%) | <0.001 | ||||
| Yes | 307 (70.7) | 93 (21.4) | 22 (5.1) | 12 (2.8) | |
| No | 309 (87.8) | 31 (8.8) | 11 (3.1) | 1 (0.3) |
Notes: *Kruskal–Wallis test, †Chi-square test.